Seeking Alpha
Long/short equity, gold, investment advisor, growth
Profile| Send Message|
( followers)  

In a recent article written about healthcare stocks with significant upside potential, I offered a fundamental and technical breakdown of four healthcare stocks trading under $15.00. After noticing continued price performance after the publication of the article, and as three of the four stocks mentioned were biotechnology stocks, I began searching for additional opportunities in the biotechnology industry. As you may have guessed, it didn't me take long to find what I was looking for.

Here is a look at six biotechnology stocks with outstanding yearly price performance and significant analyst confidence, sorted by one year return:

Ariad Pharmaceuticals, Inc. (ARIA) has grown from a $308.68 million market cap a year ago to a current market cap of $1.72 billion. The company holds a current analyst recommendation of eight strong buys and one hold, with an average price target of $13.50. The company reported a $70.70 million annual net profit last year and holds a one-year return of 320.00%, a year to date return of 155.29%, and a one-quarter return of 65.65%. Ariad Pharmaceuticals, Inc. is currently 89.69% above its 200-day simple moving average, with a short float of 11.36%.

[Click all to enlarge]

Questcor Pharmaceuticals, Inc. (QCOR) has grown from a $633.43 million market cap a year ago to a current market cap of $1.59 billion. The company holds a current analyst recommendation of four strong buys and one hold, with an average price target of $26.80. The company reported a $38.44 million annual net profit last year and holds a one-year return of 178.08%, a YTD return of 74.81%, and a one-quarter return of 34.46%. Questcor Pharmaceuticals, Inc. is currently 57.46% above its 200-day SMA with a short float of 12.73%.

Oncothyreon, Inc. (ONTY) has grown from a $85.23 million market cap a year ago to a current market cap of $367.74 million. The company holds a current analyst recommendation of four strong buys with an average price target of $11.00. Though the company reported a $21.96 million annual net loss last year, the stock holds a one-year return of 142.19%, a YTD return of 171.17%, and a one-quarter return of 115.61%. Oncothyreon, Inc. is currently 130.23% above its 200-day SMA with a short float of 16.22%.

BioSante Pharmaceuticals, Inc. (BPAX) has grown from a $124.61 million market cap a year ago to a current market cap of $347.26 million. The company holds a current analyst recommendation of five strong buys with an average price target of $5.50. Though the company reported a $52.91 million annual net loss last year, the stock holds a one-year return of 126.22%, a YTD return of 126.22%, and a one-quarter return of 75.83%. BioSante Pharmaceuticals, Inc. is currently 71.60% above its 200-day SMA with a short float of 14.90%.

Adventrx Pharmaceuticals, Inc. (ANX) has grown from a $23.31 million market cap a year ago to a current market cap of $92.38 million. The company holds a current analyst recommendation of one strong buy with a price target of $16.00. Though the company reported a $12.13 million annual net loss last year, the stock holds a one-year return of 101.73%, a YTD return of 33.72%, and a one-quarter return of 57.21%. Adventrx Pharmaceuticals, Inc. is currently 44.11% above its 200-day SMA with a short float of 7.73%.

Vical, Inc. (VICL) has grown from a $174.19 million market cap a year ago to a current market cap of $339.91 million. The company holds a current analyst recommendation of four strong buys and two holds with an average price target of $6.75. Though the company reported a $30.60 million annual net loss last year, the stock holds a one-year return of 51.44%, a YTD return of134.65 %, and a one-quarter return of 43.64%. Vical, Inc. is currently 74.72% above its 200-day SMA with a short float of 7.29%.

With a 153.28% average yearly return compared to the S&P's 24.80% yearly return, these biotechnology stocks have been performing significantly well over the past year. But will they continue to perform as they have over the past months?

From an analyst point of view, ANX, BPAX, ONTY, and VICL are the most likely candidates to continue their impressive performance. All of the four stocks are well below their respective analysts' price targets and offer us significant upside potential. ARIA and QCOR, on the other hand, are both very near their respective analysts' price targets. But both of these stocks are still currently trading within a solid, up-trending price channel so, analysts' price targets aside, I wouldn't write them off just yet.

In conclusion, if you're looking to jump on the well-performingbBiotechnology train, these six stocks may offer you a good opportunity to do so.

Source: 6 Biotech Stocks With 150% Average Yearly Return and Still Climbing